FibriCheck

TLDR

FibriCheck is a Hasselt-based medical app company that uses smartphone cameras to detect atrial fibrillation and cardiac arrhythmias, with CE marking, FDA clearance, and EUR 12.6M+ in funding.

Overview

Founded in 2014 by Lars Grieten, Bieke Van Gorp, and Jo Van Der Auwera in Hasselt, FibriCheck (operating as Qompium BV) developed a medical-grade smartphone app that uses the camera and flash to perform photoplethysmography (PPG), measuring heart rhythm without additional hardware. An AI algorithm processes the signal to detect atrial fibrillation and other arrhythmias, producing a clinical-grade report reviewable by healthcare professionals through a companion portal.

The app holds CE marking as a Class IIa medical device under the EU MDR and was the first cardiac rhythm monitoring app to receive FDA clearance in the United States. It is used by cardiologists, general practitioners, and patients across Europe and the US for between-appointment rhythm monitoring, a use case where intermittent symptoms are otherwise difficult to capture.

Funding includes early grants from Bayer (EUR 50K) and EUR 1.5M from LRM and Volta Ventures, followed by a EUR 9M round in February 2021. Total funding exceeds EUR 12.6M across six rounds.

Key People

• Lars Grieten - Co-founder, CEO
• Bieke Van Gorp - Co-founder
• Jo Van Der Auwera - Co-founder

Funding History

• Seed: EUR 50K from Bayer
• Series A (tranche 1): EUR 1.5M from LRM and Volta Ventures
• February 2021: EUR 9M (total round), Qompium
• Total: EUR 12.6M+ across 6 rounds